CL2017000478A1 - Compuesto de pirazolotiazol y medicamento que comprende el mismo. - Google Patents
Compuesto de pirazolotiazol y medicamento que comprende el mismo.Info
- Publication number
- CL2017000478A1 CL2017000478A1 CL2017000478A CL2017000478A CL2017000478A1 CL 2017000478 A1 CL2017000478 A1 CL 2017000478A1 CL 2017000478 A CL2017000478 A CL 2017000478A CL 2017000478 A CL2017000478 A CL 2017000478A CL 2017000478 A1 CL2017000478 A1 CL 2017000478A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- effect
- arrangement
- pyrazolothiazole
- medicine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE PIRAZOLOTIAZOL DE LA FORMULA (I), O UNA SAL DEL MISMO FARMACÉUTICAMENTE ACEPTABLE:</p> <p>* incluir figura de estructura de hoja resumen pagina 227 pdf total.</p> <p>EL COMPUESTO DE LA INVENCIÓN TIENE ACTIVIDAD INHIBIDORA DE JAK1, Y DE ESTE MODO, EFECTO INMUNOSUPRESOR, EFECTO ANTI INFLAMATORIO Y EFECTO ANTI-PROLIFERTATIVO, Y ES ÚTIL EN EL TRATAMIENTO DE LAS ENFERMEDADES, POR EJEMPLO, ARTRITIS REUMATOIDE, ENFERMEDAD INFLAMATORIA INTESTINAL, PSORIASIS Y VASCULITIS, ASMA BRONQUIAL, ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA Y SINUSITIS EOSOFÍLICA, PÓLIPO NASAL.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014177969 | 2014-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000478A1 true CL2017000478A1 (es) | 2017-11-10 |
Family
ID=55439874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000478A CL2017000478A1 (es) | 2014-09-02 | 2017-02-28 | Compuesto de pirazolotiazol y medicamento que comprende el mismo. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US9937176B2 (es) |
| EP (1) | EP3190116B1 (es) |
| JP (1) | JP6558372B2 (es) |
| KR (1) | KR102294330B1 (es) |
| CN (1) | CN107108653B (es) |
| AU (1) | AU2015312886B2 (es) |
| BR (1) | BR112017003800B1 (es) |
| CA (1) | CA2959721C (es) |
| CL (1) | CL2017000478A1 (es) |
| CO (1) | CO2017002982A2 (es) |
| CY (1) | CY1123320T1 (es) |
| DK (1) | DK3190116T3 (es) |
| ES (1) | ES2827243T3 (es) |
| HR (1) | HRP20201382T1 (es) |
| HU (1) | HUE050565T2 (es) |
| IL (1) | IL250729B (es) |
| LT (1) | LT3190116T (es) |
| MA (1) | MA40605B1 (es) |
| MX (1) | MX2017002488A (es) |
| MY (1) | MY181814A (es) |
| NZ (1) | NZ729494A (es) |
| PE (1) | PE20170668A1 (es) |
| PH (1) | PH12017500383B1 (es) |
| PL (1) | PL3190116T3 (es) |
| PT (1) | PT3190116T (es) |
| RS (1) | RS60798B1 (es) |
| RU (1) | RU2688660C2 (es) |
| SG (2) | SG11201701447UA (es) |
| SI (1) | SI3190116T1 (es) |
| TW (1) | TWI679205B (es) |
| UA (1) | UA121869C2 (es) |
| WO (1) | WO2016035814A1 (es) |
| ZA (1) | ZA201701492B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| US11167953B2 (en) | 2017-06-09 | 2021-11-09 | Mitsubishi Electric Corporation | Passenger conveyor |
| US20230117592A1 (en) * | 2019-12-23 | 2023-04-20 | Sri International | Lipoxygenase inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
| US5017212A (en) * | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
| US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
| GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| EP1704145B1 (en) | 2004-01-12 | 2012-06-13 | YM BioSciences Australia Pty Ltd | Selective kinase inhibitors |
| WO2005105779A1 (en) | 2004-04-28 | 2005-11-10 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
| SG151327A1 (en) * | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| PT1951684T (pt) * | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
| AR060316A1 (es) | 2006-01-17 | 2008-06-11 | Vertex Pharma | Azaindoles de utilidad como inhibidores de janus quinasas |
| ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| ES2396126T3 (es) * | 2008-04-15 | 2013-02-19 | Eisai R&D Management Co., Ltd. | Compuesto de 3-fenilpirazol[5,1-b]tiazol |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| JP5490137B2 (ja) * | 2008-12-19 | 2014-05-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害薬としての二環式ピラゾール |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| CA2782720A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| MX2012008049A (es) | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2616443A1 (en) | 2010-09-14 | 2013-07-24 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
| US8937077B2 (en) | 2010-10-22 | 2015-01-20 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/zh active
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
- 2015-09-02 PL PL15838466T patent/PL3190116T3/pl unknown
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 CA CA2959721A patent/CA2959721C/en active Active
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 MX MX2017002488A patent/MX2017002488A/es unknown
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/hu unknown
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/zh active Active
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/da active
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/ko active IP Right Grant
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/lt unknown
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/ja active Active
- 2015-09-02 ES ES15838466T patent/ES2827243T3/es active Active
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/en active Active
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/pt active IP Right Grant
- 2015-09-02 RS RS20201081A patent/RS60798B1/sr unknown
- 2015-09-02 SI SI201531340T patent/SI3190116T1/sl unknown
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/ru active
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/es unknown
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
- 2015-09-02 UA UAA201702990A patent/UA121869C2/uk unknown
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/ja active Application Filing
- 2015-09-02 MA MA40605A patent/MA40605B1/fr unknown
- 2015-09-02 PT PT158384669T patent/PT3190116T/pt unknown
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/es unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/es unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-08-31 HR HRP20201382TT patent/HRP20201382T1/hr unknown
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000478A1 (es) | Compuesto de pirazolotiazol y medicamento que comprende el mismo. | |
| CL2016002888A1 (es) | Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras. | |
| GT201600123A (es) | Inhibidores de syk | |
| CL2014000122A1 (es) | Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades. | |
| CL2015002301A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c. | |
| CL2008001593A1 (es) | Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma. | |
| CR20160327A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| CY1120974T1 (el) | Ετεροκυκλικες ενωσεις, φαρμακα που περιεχουν τις αναφερομενες ενωσεις, χρηση αυτων και διαδικασιες για την παραγωγη τους | |
| CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
| CU24103B1 (es) | Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos | |
| WO2014151456A3 (en) | Treatment of inflammatory diseases | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
| JP2016540749A5 (es) | ||
| CY1121115T1 (el) | Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα | |
| SV2019005857A (es) | Derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol..3-cinasa delta y gamma | |
| CL2017000117A1 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila. | |
| CY1123607T1 (el) | Κρυσταλλος ενωσης που εχει ανασταλτικη δραση στις jak | |
| PT110209A (pt) | Formas polimórficas de trifenatato de vilanterol e processos para a preparação das mesmas. | |
| EA201790072A1 (ru) | Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы | |
| EA201070917A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| BR112017020615A2 (pt) | análogos de indol como antagonistas receptores de 5-oxo-ete e métodos de uso dos mesmos | |
| CO6741219A2 (es) | Inhibidores de catepsina c | |
| UY32827A (es) | Inhibidores de catepsina c |